Diane Meegan Net Worth

The estimated Net Worth of Diane Marie Meegan is at least $12.3 mil dollars as of 10 April 2015. Ms. Meegan owns over 1,000 units of Daxor stock worth over $4,570 and over the last 10 years she sold DXR stock worth over $7,690. In addition, she makes $0 as IR Contact Officer at Daxor.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Meegan DXR stock SEC Form 4 insiders trading

Diane has made over 2 trades of the Daxor stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 1,000 units of DXR stock worth $7,690 on 10 April 2015.

The largest trade she's ever made was buying 1,500 units of Daxor stock on 19 February 2015 worth over $8,850. On average, Diane trades about 1,250 units every 25 days since 2015. As of 10 April 2015 she still owns at least 500 units of Daxor stock.

You can see the complete history of Ms. Meegan stock trades at the bottom of the page.

Diane Meegan biography

Diane Meegan is IR Contact Officer of Daxor Corporation. Ms. Meegan was Secretary at Daxor Corporation till 2006. Ms. Meegan joined Daxor Corporation in February 2002, as the Senior Executive Assistant to the CEO and President served untill 2002. Ms. Meegan served as the Official Executive Assistant to the CEO of Newbridge Securities, a wholly owned subsidiary of Citigroup, for 13 years. For 4 years, she served as a member of their Problem Review Board. Ms. Meegan also served as the Executive Assistant to the Head of Operations at Instinet Clearing Services. She functions in the capacity of a senior administrative assistant.

What's Diane Meegan's mailing address?

Diane's mailing address filed with the SEC is 259 NEW YORK AVENUE, , JERSEY CITY, NJ, 07307.

Insiders trading at Daxor

Over the last 21 years, insiders at Daxor have traded over $7,541,627 worth of Daxor stock and bought 473,408 units worth $2,888,339 . The most active insiders traders include Joseph Feldschuh, Bruce Slovin, eRobert J Michel. On average, Daxor executives and independent directors trade stock every 39 days with the average trade being worth of $27,740. The most recent stock trade was executed by Robert J Michel on 27 March 2024, trading 750 units of DXR stock currently worth $6,525.

What does Daxor do?

the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.

Complete history of Ms. Meegan stock trades at Daxor

Daxor executives and stock owners

Daxor executives and other stock owners filed with the SEC include:

• Jonathan Adam Feldschuh,
  Chief Scientific Officer & Director
• Michael Richard Feldschuh,
  Chairman, Pres & CEO
• Diane Meegan,
  IR Contact Officer
• Robert Willens,
  Independent Director
• James Lombard,
  Independent Director
• Joy Goudie,
  Independent Director
• Edward Feuer,
  Director
• Henry Cremisi,
  Director
• Jonathan Feldschuh,
  Chief Scientific Officer, Director
• Robert Michel,
  Chief Financial Officer
• Michael Feldschuh,
  Chairman of the Board, President, Chief Executive Officer
• Robert J. Michel M.B.A., CPA, CPA,
  CFO, Chief Compliance Officer & Corp. Sec.
• Guido Manzo,
  VP of Sales
• Kathryn A. Kornafel,
  VP of Marketing & Commercial Devel.
• Robert J. Michel M.B.A., C.P.A., CPA,
  CFO, Chief Compliance Officer & Corp. Sec.
• Caleb Des Rosiers,
  Director
• Of Joseph Feldschuh Estate,
  10% owner
• Bernhard Saxe,
  Director
• Soren Thompson,
  VP, Business Development
• Everis Engstrom,
  Vice President
• Robert G Moussa,
  Director
• Martin S Wolpoff,
  Director
• Philip Nordan Hudson,
  Director
• Joseph Feldschuh,
  President & CEO
• Stephen Valentine,
  Director
• Bruce Slovin,
  Director
• Gary Joseph Fischman,
  President